Peter Neumann in New England Journal of Medicine: Cost-Effectiveness 2.0 -- Poised for a Second Act?
PHE Scientific Advisor Peter Neumann, along with co-author Gillian Sanders, offers a new perspective on cost-effectiveness analysis, just published in the New England Journal of Medicine. Neumann and Sanders provide an overview of recent work, and argue that cost-effectiveness analysis should be an essential part of healthcare decision making.
To read the article, please click here.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.